Nanocarriers modified with a protease-resistant BBB shuttle for targeted CNS drug delivery in diffuse intrinsic pontine glioma. – Cure2DIPG
Angel M Carcaboso (Divers public)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
INSERM Institut National de la Santé et de la Recherche Médicale
Institute for Research in Biomedicine (IRB Barcelona)
TECHNION-Israël INSTITUTE OF TECHNOLOGY (Israël)
Help of the ANR 209,616 euros
Beginning and duration of the scientific project: December 2015 - 36 Months